Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans

Molecular Psychiatry

Volumn 19, Issue 5, 2014, Pages 625-632

  Hulka, L M ^a   Treyer, V ^b   Scheidegger, M ^c,d   Preller, K H ^a   Vonmoos, M ^a   Baumgartner, M R ^e   Johayem, A ^e   Ametamey, S M ^e   Buck, A ^b,e   Seifritz, E ^c,e   Quednow, B B ^a,e  

^a University Hospital of Psychiatry Zurich   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Department of Psychiatry Psychotherapy and Psychosomatics University Hospital of Psychiatry Zurich ^*  (Switzerland)

^d ETH ZURICH   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

addiction; cocaine; glutamate; nicotine; PET; treatment

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; COCAINE; METABOTROPIC RECEPTOR 5; RADIOPHARMACEUTICAL AGENT; 3-(6-METHYLPYRIDIN-2-YLETHYNYL)CYCLOHEX-2-ENONE-O-METHYLOXIME; OXIME; PYRIDINE DERIVATIVE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; AMYGDALOID NUCLEUS; ARTICLE; BRAIN REGION; CANNABIS USE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COCAINE DEPENDENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG USE; EDUCATION; EDUCATIONAL STATUS; HIPPOCAMPUS; HUMAN; INSULA; MALE; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR DENSITY; SMOKING; SMOKING CESSATION; THALAMUS; TOBACCO DEPENDENCE; TREATMENT DURATION; BRAIN SIZE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DEPENDENCE; EFFECT SIZE; HAIR ANALYSIS; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; SELF REPORT; TOXICOLOGY; WHOLE BODY SCANNER; BRAIN; BRAIN CORTEX; DIAGNOSTIC USE; INTERVIEW; METABOLISM; SCINTISCANNING; TIME;

ADULT; BRAIN; CAUDATE NUCLEUS; CEREBRAL CORTEX; COCAINE-RELATED DISORDERS; HUMANS; INTERVIEWS AS TOPIC; MALE; OXIMES; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, METABOTROPIC GLUTAMATE 5; SELF REPORT; SMOKING; TIME FACTORS; TOBACCO USE DISORDER;

EID: 84899493787     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.51     Document Type: Article

References (74)

1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contributionto the global burden of disease. Lancet 2012; 379: 55-70.
2. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic costof brain disorders in Europe. Eur J Neurol 2012; 19: 155-162.
3. UNODC. World Drug Report. Geneva, Switzerland, 2012.
4. SAMHSA. Treatment Episode Data Set (TEDS) 1998-2008. Rockville, MD, USA,2010.
5. EMCDDA. Annual report 2011: The state of the drug problem in Europe.Luxembourg, 2011.
6. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for thetreatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012;100: 801-810.
7. Volkow ND, Wang GJ, Fowler JS, Tomasi D. Addiction circuitry in the human brain.Annu Rev Pharmacol Toxicol 2012; 52: 321-336.
8. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: fromactions to habits to compulsion. Nat Neurosci 2005; 8: 1481-1489. (Pubitemid 41573659)
9. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci2009; 10: 561-572.
10. Nestler EJ. Common molecular and cellular substrates of addiction and memory.Neurobiol Learn Mem 2002; 78: 637-647. (Pubitemid 36268684)
11. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core ofthe nucleus accumbens mediates cocaine-induced reinstatement of drug-seekingbehavior. J Neurosci 2003; 23: 3531-3537. (Pubitemid 36531996)
12. Ary AW, Szumlinski KK. Regional differences in the effects of withdrawal fromrepeated cocaine upon Homer and glutamate receptor expression: a two-speciescomparison. Brain Res 2007; 1184: 295-305. (Pubitemid 350160565)
13. Ben-Shahar O, Obara I, Ary AW, Ma N, Mangiardi MA, Medina RL et al. Extendeddaily access to cocaine results in distinct alterations in Homer 1b/c and NMDAreceptor subunit expression within the medial prefrontal cortex. Synapse 2009;63: 598-609.
14. Fourgeaud L, Mato S, Bouchet D, Hemar A, Worley PF, Manzoni OJ. A single in vivoexposure to cocaine abolishes endocannabinoid-mediated long-term depressionin the nucleus accumbens. J Neurosci 2004; 24: 6939-6945. (Pubitemid 39045451)
15. Ghasemzadeh MB, Vasudevan P, Mueller C, Seubert C, Mantsch JR. Neuroadaptationsin the cellular and postsynaptic group 1 metabotropic glutamatereceptor mGluR5 and Homer proteins following extinction of cocaine selfadministrationNeurosci Lett 2009; 452: 167-171.
16. Hao Y, Martin-Fardon R, Weiss F. Behavioral and functional evidence ofmetabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5dysregulation in cocaine-escalated rats: factor in the transition to dependence.Biol Psychiatry 2010; 68: 240-248.
17. Swanson CJ, Baker DA, Carson D, Worley PF, Kalivas PW. Repeated cocaineadministration attenuates group I metabotropic glutamate receptor-mediatedglutamate release and behavioral activation: a potential role for Homer. J Neurosci2001; 21: 9043-9052. (Pubitemid 33054866)
18. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S. Molecularcharacterization of a novel metabotropic glutamate receptor mGluR5 coupledto inositol phosphate/Ca2\+ signal transduction. J Biol Chem 1992; 267:13361-13368.
19. Bellone C, Mameli M. mGluR-Dependent Synaptic Plasticity in Drug-Seeking. FrontPharmacol 2012; 3: 159.
20. Duncan JR, Lawrence AJ. The role of metabotropic glutamate receptors inaddiction: evidence from preclinical models. Pharmacol Biochem Behav 2012; 100:811-824.
21. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S et al.Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 nullmutant mice. Nat Neurosci 2001; 4: 873-874. (Pubitemid 32801588)
22. Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptorantagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology2006; 31: 778-786.
23. Besheer J, Faccidomo S, Grondin JJ, Hodge CW. Regulation of motivation toself-administer ethanol by mGluR5 in alcohol-preferring (P) rats. Alcohol Clin ExpRes 2008; 32: 209-221.
24. Gass JT, Osborne MP, Watson NL, Brown JL, Olive MF. mGluR5 antagonismattenuates methamphetamine reinforcement and prevents reinstatement ofmethamphetamine-seeking behavior in rats. Neuropsychopharmacology 2009; 34:820-833.
25. Kenny PJ, Boutrel B, Gasparini F, Koob GF, Markou A. Metabotropicglutamate 5 receptor blockade may attenuate cocaine self-administrationby decreasing brain reward function in rats. Psychopharmacology 2005; 179:247-254. (Pubitemid 40576712)
26. Kumaresan V, Yuan M, Yee J, Famous KR, Anderson SM, Schmidt HD et al.Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocainepriming-and cue-induced reinstatement of cocaine seeking. Behav Brain Res2009; 202: 238-244.
27. Lee B, Platt DM, Rowlett JK, Adewale AS, Spealman RD. Attenuation of behavioraleffects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine.J Pharmacol Exp Ther 2005; 312: 1232-1240. (Pubitemid 40293785)
28. Martin-Fardon R, Baptista MA, Dayas CV, Weiss F. Dissociation of the effects ofMTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatementand reinforcement: comparison between cocaine and a conventionalreinforcer. J Pharmacol Exp Ther 2009; 329: 1084-1090.
29. Paterson NE, Markou A. The metabotropic glutamate receptor 5 antagonist MPEPdecreased break points for nicotine, cocaine and food in rats. Psychopharmacology2005; 179: 255-261. (Pubitemid 40576713)
30. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEPdecreased nicotine self-administration in rats and mice. Psychopharmacology2003; 167: 257-264. (Pubitemid 36712972)
31. Platt DM, Rowlett JK, Spealman RD. Attenuation of cocaine self-administration insquirrel monkeys following repeated administration of the mGluR5 antagonistMPEP: comparison with dizocilpine. Psychopharmacology 2008; 200: 167-176.
32. van der Kam EL, de Vry J, Tzschentke TM. Effect of 2-methyl-6- (phenylethynyl)pyridine on intravenous self-administration of ketamine and heroin in the rat.Behav Pharmacol 2007; 18: 717-724. (Pubitemid 350076428)
33. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S et al.Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imagingthe metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47: 698-705. (Pubitemid 46768472)
34. Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M et al. HumanPET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688.J Nucl Med 2007; 48: 247-252. (Pubitemid 47555351)
35. Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D et al. Markedglobal reduction in mGluR5 receptor binding in smokers and ex-smokers determinedby [11C]ABP688 positron emission tomography. Proc Natl Acad Sci USA2013; 110: 737-742.
36. Hulka LM, Wagner M, Preller KH, Jenni D, Quednow BB. Blue-yellow colour visionimpairment and cognitive deficits in occasional and dependent stimulant users.Int J Neuropsychopharmacol 2013; 16: 535-547.
37. Preller KH, Ingold N, Hulka LM, Vonmoos M, Jenni D, Baumgartner MR et al.Increased sensorimotor gating in recreational and dependent cocaine users ismodulated by craving and attention-deficit/hyperactivity disorder symptoms. BiolPsychiatry 2013; 73: 225-234.
38. Vonmoos M, Hulka LM, Preller KH, Jenni D, Baumgartner MR, Stohler R et al.Cognitive dysfunctions in recreational and dependent cocaine users: role ofattention-deficit hyperactivity disorder, craving and early age at onset. Br J Psychiatry;doi: 10.1192/bjp.bp.112.118091 (in press).
39. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. SKID-I. Strukturiertes KlinischesInterview fu? r DSM-IV Achse I: Psychische Sto? rungen. Interviewheft undBeurteilungsheft. Hogrefe: Go? ttingen, Germany 1997.
40. Quednow BB, Kuhn KU, Hoenig K, Maier W, Wagner M. Prepulse inhibition andhabituation of acoustic startle response in male MDMA ('ecstasy') users, cannabisusers, and healthy controls. Neuropsychopharmacology 2004; 29: 982-990. (Pubitemid 38526798)
41. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuringdepression. Arch Gen Psychiatry 1961; 4: 561-571.
42. Franke G. SCL-90-R: Die Symptom-Check-Liste von Derogatis-German Version.Beltz Test Gesellschaft: Go? ttingen, Germany 1995.
43. Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. Thevalidity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend2006; 83: 233-237.
44. Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of acocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19-28.
45. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Testfor Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire.Br J Addict 1991; 86: 1119-1127.
46. Burger C, Deschwanden A, Ametamey S, Johayem A, Mancosu B, Wyss M et al.Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5.Nucl Med Biol 2010; 37: 845-851.
47. Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U et al. Evaluation ofthe metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688:assessment of methods. J Nucl Med 2007; 48: 1207-1215. (Pubitemid 47052662)
48. Blasberg RG, Carson RE, Kawai R, Patlak CG, Sawada Y, Channing MA et al.Strategies for the study of the opiate receptor in brain: application to the opiateantagonist cyclofoxy. J Cereb Blood Flow Metab 1989; 9: 732.
49. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC et al. Comparisonof bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxyand positron emission tomography. J Cereb Blood Flow Metab 1993; 13: 24-42. (Pubitemid 23016600)
50. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix Net al. Automated anatomical labeling of activations in SPM using a macroscopicanatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15:273-289. (Pubitemid 34852226)
51. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensusnomenclature for in vivo imaging of reversibly binding radioligands. J Cereb BloodFlow Metab 2007; 27: 1533-1539. (Pubitemid 47301451)
52. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem Aet al. Reduced metabotropic glutamate receptor 5 density in major depressiondetermined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 2011;168: 727-734.
53. Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM et al. Increasedmetabotropic glutamate receptor subtype 5 availability in human brain after onenight without sleep. Biol Psychiatry 2013; 73: 161-168.
54. Elmenhorst D, Minuzzi L, Aliaga A, Rowley J, Massarweh G, Diksic M et al. In vivoand in vitro validation of reference tissue models for the mGluR(5) ligand[(11)C]ABP688. J Cereb Blood Flow Metab 2010; 30: 1538-1549.
55. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical poweranalysis program for the social, behavioral, and biomedical sciences. Behav ResMeth 2007; 39: 175-191.
56. DeLorenzo C, Kumar JS, Mann JJ, Parsey RV. In vivo variation in metabotropicglutamate receptor subtype 5 binding using positron emission tomography and[11C]ABP688. J Cereb Blood Flow Metab 2011; 31: 2169-2180.
57. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization ofG protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004; 27:107-144. (Pubitemid 39050399)
58. Dhami GK, Ferguson SS. Regulation of metabotropic glutamate receptor signaling,desensitization and endocytosis. Pharmacol Ther 2006; 111: 260-271. (Pubitemid 43765534)
59. Fourgeaud L, Bessis AS, Rossignol F, Pin JP, Olivo-Marin JC, Hemar A. The metabotropicglutamate receptor mGluR5 is endocytosed by a clathrin- independentpathway. J Biol Chem 2003; 278: 12222-12230. (Pubitemid 36800203)
60. Trivedi RR, Bhattacharyya S. Constitutive internalization and recycling ofmetabotropic glutamate receptor 5 (mGluR5). Biochem Biophys Res Commun 2012;427: 185-190.
61. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropicglutamate receptors. Trends Pharmacol Sci 2004; 25: 265-272. (Pubitemid 38553829)
62. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S et al. Neuroadaptationsin cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003; 6:743-749. (Pubitemid 36792890)
63. Kalivas PW, Brady K. Getting to the core of addiction: hatching the addiction egg.Nat Med 2012; 18: 502-503.
64. Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M et al.Repeated N-acetylcysteine administration alters plasticity-dependent effects ofcocaine. J Neurosci 2007; 27: 13968-13976. (Pubitemid 351377873)
65. Miguens M, Del Olmo N, Higuera-Matas A, Torres I, Garcia-Lecumberri C, AmbrosioE. Glutamate and aspartate levels in the nucleus accumbens during cocaineself-administration and extinction: a time course microdialysis study.Psychopharmacology 2008; 196: 303-313.
66. Kalivas PW, Volkow ND. New medications for drug addiction hiding inglutamatergic neuroplasticity. Mol Psychiatry 2011; 16: 974-986.
67. Bierut LJ, Rice JP, Goate A, Hinrichs AL, Saccone NL, Foroud T et al. A genomicscan for habitual smoking in families of alcoholics: common and specific geneticfactors in substance dependence. Am J Med Genet A 2004; 124A: 19-27. (Pubitemid 38139811)
68. Stoker AK, Olivier B, Markou A. Involvement of metabotropic glutamate receptor 5in brain reward deficits associated with cocaine and nicotine withdrawal andsomatic signs of nicotine withdrawal. Psychopharmacology 2012; 221: 317-327.
69. Schmidt K, Krishnan B, Xia Y, Sun A, Orozco-Cabal L, Pollandt S et al. Cocainewithdrawal reduces group I mGluR-mediated long-term potentiation viadecreased GABAergic transmission in the amygdala. Eur J Neurosci 2011; 34:177-189.
70. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotineaddiction. J Neurobiol 2002; 53: 606-617.
71. Telang FW, Volkow ND, Levy A, Logan J, Fowler JS, Felder C et al. Distribution oftracer levels of cocaine in the human brain as assessed with averaged[11C]cocaine images. Synapse 1999; 31: 290-296. (Pubitemid 29070290)
72. Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences inmGluR5 binding sites in mammalian central nervous system determined usingin vitro binding with [18F]F-PEB. Nucl Med Biol 2007; 34: 1009-1017. (Pubitemid 350061172)
73. Barret O, Tamagnan G, Batis J, Jennings D, Zubal G, Russell D et al. Quantitation ofglutamate mGluR5 receptor with 18F-FPEB PET in humans. J Nucl Med 2010;51(Supplement 2): 215.
74. Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ et al. Synthesis,characterization, and first successful monkey imaging studies of metabotropic glutamatereceptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005; 56: 205-216. (Pubitemid 40656643)